Skip to main content
Premium Trial:

Request an Annual Quote

New Products: GeneDx's Mito101

Premium

GeneDx has launched Mito101, a sequencing-based diagnostic that targets 101 nuclear genes associated with mitochondrial disorders. The test expands on the company's current Mito24 test, which targets just 24 genes.

Mito101 targets 1,000 exons from 101 genes and disease-associated variants are verified with Sanger sequencing. It has a turnaround time of around 10 weeks and a contract price of $6,500.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.